Rheumatoid arthritis is a chronic, inflammatory, autimmune, systemic disease that affects approximately 2 million Americans.
According to a study of 1,315 patients with rheumatoid arthritis participating in the Alberta Biologics Pharmacosurveillance program, patients with who go into remission have increased levels of activity and fewer long term costs.
According to the study’s lead author, Dr. Cheryl Barnabe, patients who achieved remission on biologic therapy had fewer hospitalizations, lower monthly cost for over-the-counter medication, needed less help from others for activities of daily living, and fewer lost hours from work compared with patients with moderate to high levels of disease.
For more information on rheumatoid arthritis treatments and other arthritis problems go to:
Just go here Contact